Get all the most recent news on coronavirus and more provided daily to your inbox. Sign up here
Gilead Sciences is responding to a World Health Organization report that its experimental antiviral drug failed to help clients with extreme COVID-19 in a medical trial performed in China.
Gilead said the findings were inconclusive because the study was terminated early.
GET FOX COMPANY ON THE GO BY CLICK ON THIS LINK
The antiviral drug remdesivir is utilized to treat malaria. According to the study, it did not assist speed the recovery of COVID-19 patients, according to FT and Stat News. A summary of the report was at first shared by the WHO before it was removed.
A WHO spokesperson confirmed to FOX Company that the report was shared early and removed.
| Ticker | Security | Last | Change | Modification % |
|---|---|---|---|---|
| GILD | GILEAD SCIENCES INC. | 7778 | -3.53 | -4.34% |
” We believe the post consisted of unsuitable characterizations of the study. The research study was ended early due to low enrollment and, as a result, it was underpowered to allow statistically meaningful conclusions,” according to a Gilead declaration.” As such, the research study outcomes are inconclusive, though patterns in the information suggest a prospective benefit for remdesivir, particularly amongst patients treated early in illness.”
RENOWNED ECONOMIC EXPERT COMPOSES $100 B CORONAVIRUS STRATEGY TO TEST ALL AMERICANS
The summary originated from one of two Chinese remdesivir trials that were suspended early because there were not enough patients offered.
CORONAVIRUS PATIENT RESEARCH STUDY RAISES CONCERNS ABOUT WHETHER TEMPERATURE CHECKS WORK
Recently, Stat reported arise from another medical remdesivir trial performed by the University of Chicago Medication, which found nearly all patients who were given everyday infusions of Remdesivir were discharged from the healthcare facility in less than a week.
There are multiple Stage 3 research studies underway.
CLICK ON THIS LINK TO LEARN MORE ON FOX BUSINESS
In a statement, Gilead stated “These research studies will assist inform whom to deal with, when to deal with and for how long to treat with remdesivir. The studies are either fully registered for the primary analysis or on track to fully enlist in the future.”
Gilead stated it will have more trial results to share at the end of the month.
FOX Business’ Audrey Conklin contributed to this post.
